



SEQUENCE LISTING

<110> WOULFE, SUSAN L.
JAIN, RITA
BURR, AIMEE

<120> ENGINEERED FAB' FRAGMENT ANTI-TUMOR
NECROSIS FACTOR ALPHA IN COMBINATION WITH DISEASE MODIFYING
ANTI-RHEUMATIC DRUGS

<130> 122294-1010

<140> US/10/728,420

<141> 2003-12-05

<150> US 60/431,053

<151> 2002-12-05

<160> 40

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Mouse monoclonal antibody hTNF40 CDRH1

<400> 1

Asp Tyr Gly Met Asn

1

5

<210> 2

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Mouse monoclonal antibody hTNF40/human hybrid CDRH2

<400> 2

Trp Ile Asn Thr Tyr Ile Gly Glu Pro Ile Tyr Ala Asp Ser Val Lys

1

5

10

15

Gly

<210> 3

<211> 9

<212> PRT

<213> Artificial Sequence

<220>
<223> Mouse monoclonal antibody hTNF40 CDRH3

<400> 3
Gly Tyr Arg Ser Tyr Ala Met Asp Tyr
1 5

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Mouse monoclonal antibody hTNF40 CDRL1

<400> 4
Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala
1 5 10

<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Mouse monoclonal antibody hTNF40 CDRL2

<400> 5
Ser Ala Ser Phe Leu Tyr Ser
1 5

<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mouse monoclonal antibody hTNF40 CDRL3

<400> 6
Gln Gln Tyr Asn Ile Tyr Pro Leu Thr
1 5

<210> 7
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Mouse monoclonal antibody hTNF40 CDRH2

<400> 7

Trp Ile Asn Thr Tyr Ile Gly Glu Pro Ile Tyr Val Asp Asp Phe Lys
 1 5 10 15
 Gly

<210> 8
 <211> 321
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> CDS

<222> (1)...(321)
 <223> Synthetic hTNF40-gL1

<400> 8
 gac att caa atg acc cag agc cca tcc agc ctg agc gca tct gta gga 48
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 gac cgg gtc acc atc act tgt aaa gcc agt cag aac gta ggt act aac 96
 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn
 20 25 30
 gta gcc tgg tat cag caa aaa cca ggt aaa gcc cca aaa gcc ctc atc 144
 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ala Leu Ile
 35 40 45
 tac agt gcc tct ttc ctc tat agt ggt gta cca tac agg ttc agc gga 192
 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Tyr Arg Phe Ser Gly
 50 55 60
 tcc ggt agt ggt act gat ttc acc ctc acg atc agt agc ctc cag cca 240
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 gaa gat ttc gcc act tat tac tgt caa cag tat aac atc tac cca ctc 288
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ile Tyr Pro Leu
 85 90 95
 aca ttc ggt cag ggt act aaa gta gaa atc aaa 321
 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 9
 <400> 9
 000

<210> 10
 <400> 10
 000

<210> 11

<211> 354
<212> DNA
<213> Artificial Sequence

<220>
<221> CDS
<222> (1)...(354)
<223> Synthetic gh3hTNF40.4

<223> Grafted Heavy Chain for Modified Fab

<400> 11
gag gtt cag ctg gtc gag tca gga ggc ggt ctc gtg cag cct ggc gga 48
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

tca ctg aga ttg tcc tgt gct gca tct ggt tac gtc ttc aca gac tat 96
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Val Phe Thr Asp Tyr
20 25 30

gga atg aat tgg gtt aga cag gcc ccg gga aag ggc ctg gaa tgg atg 144
Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

ggt tgg att aat act tac att gga gag cct att tat gct gac agc gtc 192
Gly Trp Ile Asn Thr Tyr Ile Gly Glu Pro Ile Tyr Ala Asp Ser Val
50 55 60

aag ggc aga ttc acg ttc tct cta gac aca tcc aag tca aca gca tac 240
Lys Gly Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80

ctc caa atg aat agc ctg aga gca gag gac acc gca gtg tac tat tgt 288
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

gct aga gga tac aga tct tat gcc atg gac tac tgg ggc cag ggt acc 336
Ala Arg Gly Tyr Arg Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr
100 105 110

cta gtc aca gtc tcc tca 354
Leu Val Thr Val Ser Ser
115

<210> 12
<400> 12
000

<210> 13
<400> 13
000

<210> 14

<400> 14
000

<210> 15
<400> 15
000

<210> 16
<400> 16
000

<210> 17
<400> 17
000

<210> 18
<400> 18
000

<210> 19
<400> 19
000

<210> 20
<400> 20
000

<210> 21
<400> 21
000

<210> 22
<400> 22
000

<210> 23
<400> 23
000

<210> 24
<400> 24
000

<210> 25
<400> 25
000

<210> 26
<400> 26
000

<210> 27
<400> 27
000

<210> 28
<400> 28
000

<210> 29
<400> 29
000

<210> 30
<400> 30
000

<210> 31
<400> 31
000

<210> 32
<400> 32
000

<210> 33
<400> 33
000

<210> 34
<400> 34
000

<210> 35
<400> 35
000

<210> 36
<400> 36
000

<210> 37
<400> 37
000

<210> 38
<400> 38
000

<210> 39
<400> 39
000

<210> 40
<400> 40
000

<210> 41
<400> 41
000

<210> 42
<400> 42
000

<210> 43
<400> 43
000

<210> 44
<400> 44
000

<210> 45
<400> 45
000

<210> 46
<210> 46
000

<210> 47
<400> 47
000

<210> 48
<400> 48

000

<210> 49
<400> 49
000

<210> 50
<400> 50
000

<210> 51
<400> 51
000

<210> 52
<400> 52
000

<210> 53
<400> 53
000

<210> 54
<400> 54
000

<210> 55
<400> 55
000

<210> 56
<400> 56
000

<210> 57
<400> 57
000

<210> 58
<400> 58
000

<210> 59
<400> 59
000

<210> 60
<400> 60
000

<210> 61
<400> 61
000

<210> 62
<400> 62
000

<210> 63
<400> 63
000

<210> 64
<400> 64
000

<210> 65
<400> 65
000

<210> 66
<400> 66
000

<210> 67
<400> 67
000

<210> 68
<400> 68
000

<210> 69
<400> 69
000

<210> 70
<400> 70
000

<210> 71

<400> 71
000

<210> 72
<400> 72
000

<210> 73
<400> 73
000

<210> 74
<400> 74
000

<210> 75
<400> 75
000

<210> 76
<400> 76
000

<210> 77
<400> 77
000

<210> 78
<400> 78
000

<210> 79
<400> 79
000

<210> 80
<400> 80
000

<210> 81
<400> 81
000

<210> 82
<400> 82
000

<210> 83
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> human group 1 consensus framework L1

<400> 83
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys
20

<210> 84
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Human hTNF40 framework L1

<400> 84
Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly
1 5 10 15
Asp Arg Val Ser Val Thr Cys
20

<210> 85
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> human group 1 consensus framework L2

<400> 85
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
1 5 10 15

<210> 86
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Human hTNF40 framework L2

<400> 86
Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr
1 5 10 15

<210> 87
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> human group 1 consensus framework L3

<400> 87
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15
Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
20 25 30

<210> 88
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Human hTNF40 framework L3

<400> 88
Gly Val Pro Tyr Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15
Leu Thr Ile Ser Thr Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys
20 25 30

<210> 89
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> human group 1 consensus framework L4

<400> 89
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
1 5 10

<210> 90
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Human hTNF40 framework L4

<400> 90
Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg
1 5 10

<210> 91
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> human group 1 consensus framework H1

<400> 91
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
20 25 30

<210> 92
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> Human hTNF40 framework H1

<400> 92
Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1 5 10 15
Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Val Phe Thr
20 25 30

<210> 93
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> human group 1 consensus framework H2

<400> 93
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly
1 5 10

<210> 94
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Human hTNF40 framework H2

<400> 94
Trp Val Lys Gln Ala Pro Gly Lys Ala Phe Lys Trp Met Gly
1 5 10

<210> 95
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> human group 1 consensus framework H3

<400> 95
Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu
1 5 10 15
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 96
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Human hTNF40 framework H3

<400> 96
Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Phe Leu Gln
1 5 10 15
Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg
20 25 30

<210> 97
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> human group 1 consensus framework H4

<400> 97
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10

<210> 98
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> human group 1 consensus framework H4

<400> 98
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10

<210> 99

<211> 324
<212> DNA
<213> murine

<220>
<221> CDS
<222> (1)...(324)
<223> mouse hTNF40 light chain variable domain

<400> 99
gac att gtg atg acc cag tct caa aaa ttc atg tcc aca tca gta gga 48
Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly
1 5 10 15

gac agg gtc agc gtc acc tgc aag gcc agt cag aat gtg ggt act aat 96
Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn
20 25 30

gta gcc tgg tat caa cag aaa cca gga caa tct cct aaa gca ctg aat 144
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Asn
35 40 45

tac tcg gca tcc ttc cta tat agt gga gtc cct tat cgc ttc aca ggc 192
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Tyr Arg Phe Thr Gly
50 55 60

agt gga tct ggg aca gat ttc act ctc acc atc agc act gtg cag tct 240
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Thr Val Gln Ser
65 70 75 80

gaa gac ttg gca gag tat ttc tgt cag caa tat aac atc tat cct ctc 288
Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ile Tyr Pro Leu
85 90 95

acg ttc ggt gct ggg acc aag ctg gag ctg aaa cgt 324
Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg
100 105

<210> 100
<211> 354
<212> DNA
<213> murine

<220>
<221> CDS
<222> (1)...(354)
<223> mouse hTNF40 heavy chain variable domain

<400> 100
cag atc cag ttg gtg cag tct gga cct gag ctg aag aag cct gga gag 48
Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1 5 10 15

aca gtc aag atc tcc tgc aag gct tct gga tat gtt ttc aca gac tat 96
Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Val Phe Thr Asp Tyr
20 25 30

gga atg aat tgg gtg aag cag gct cca gga aag gct ttc aag tgg atg	144
Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Ala Phe Lys Trp Met	
35 40 45	

ggc tgg ata aac acc tac att gga gag cca ata tat gtt gat gac ttc	192
Gly Trp Ile Asn Thr Tyr Ile Gly Glu Pro Ile Tyr Val Asp Asp Phe	
50 55 60	

aag gga cga ttt gcc ttc tct ttg gaa acc tct gcc agc act gcc ttt	240
Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Phe	
65 70 75 80	

ttg cag atc aac aac ctc aaa aat gag gac acg gct aca tat ttc tgt	288
Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys	
85 90 95	

gca aga ggt tac cgg tcc tat gct atg gac tac tgg ggt caa gga acc	336
Ala Arg Gly Tyr Arg Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr	
100 105 110	

tca gtc acc gtc tct tca	354
Ser Val Thr Val Ser Ser	
115	

<210> 101
 <211> 84
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Ompa oligonucleotide adaptor

<221> CDS
 <222> (29)...(0)
 <223> 67

<400> 101	
tcgagttcta gataacgagg cgtaaaaaat gaaaaagaca gctatcgcaa ttgcagtggc	60
cttggctctg acgtacgagt cagg	84

<210> 102
 <211> 67
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> CDS
 <222> (2)...(40)

<221> CDS
 <222> (43)...(66)

<223> IGS cassette-1

<400> 102
g agc tca cca gta aca aaa agt ttt aat aga gga gag tgt ta atg aag 48
Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Met Lys
1 5 10 15

aag act gct ata gca att g 67
Lys Thr Ala Ile Ala Ile
20

<210> 103
<211> 69
<212> DNA
<213> Artificial Sequence

<220>
<221> CDS
<222> (2)...(43)

<221> CDS
<222> (45)...(68)

<223> IGS cassette-2

<400> 103
g agc tca cca gta aca aaa agt ttt aat aga ggg gag tgt taa 43
Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys *
1 5 10

a atg aag aag act gct ata gca att g 69
Met Lys Lys Thr Ala Ile Ala Ile
15 20

<210> 104
<211> 81
<212> DNA
<213> Artificial Sequence

<220>
<221> CDS
<222> (2)...(43)

<221> CDS
<222> (57)...(80)

<223> IGS cassette-3

<400> 104
g agc tca cca gta aca aaa agc ttt aat aga gga gag tgt tga 43
Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys *
1 5 10

ggaggaaaaa aaa atg aag aaa act gct ata gca att g 81
Met Lys Lys Thr Ala Ile Ala Ile
15 20

<210> 105
<211> 81
<212> DNA
<213> Artificial Sequence

<220>
<221> CDS
<222> (2)...(43)

<221> CDS
<222> (57)...(80)

<223> IGS cassette-4

<400> 105
g agc tca cca gta aca aaa agt ttt aat aga gga gag tgt tga 43
Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys *
1 5 10

cgaggattat ata atg aag aaa act gct ata gca att g 81
Met Lys Lys Thr Ala Ile Ala Ile
15 20

<210> 106
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> human group 3 consensus framework H1

<400> 106
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
20 25 30

<210> 107
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> human group 3 consensus framework H2

<400> 107
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser
1 5 10

<210> 108
<211> 32
<212> PRT

<213> Artificial Sequence

<220>

<223> human group 3 consensus framework H3

<400> 108

Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	Leu	Gln
1				5					10					15	
Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Arg
			20					25					30		

<210> 109

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> human group 3 consensus framework H4

<400> 109

Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser
1				5					10	

<210> 110

<400> 110

000

<210> 111

<400> 111

000

<210> 112

<400> 112

000

<210> 113

<211> 214

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic CDP870 Light chain mature protein sequence

<400> 113

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
1				5					10					15	
Asp	Arg	Val	Thr	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Asn	Val	Gly	Thr	Asn
			20					25					30		
Val	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Ala	Leu	Ile
		35				40				45					
Tyr	Ser	Ala	Ser	Phe	Leu	Tyr	Ser	Gly	Val	Pro	Tyr	Arg	Phe	Ser	Gly
	50					55				60					

Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
65					70					75					80
Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Tyr	Asn	Ile	Tyr	Pro	Leu
				85					90					95	
Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala
			100					105					110		
Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly
		115					120					125			
Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala
	130					135					140				
Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln
145					150					155					160
Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser
			165						170					175	
Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr
		180						185					190		
Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser
	195						200					205			
Phe	Asn	Arg	Gly	Glu	Cys										
	210														

<210> 114
 <400> 114
 000

<210> 115
 <211> 229
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic CDP870 Heavy chain mature protein sequence

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1				5					10					15	
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Tyr	Val	Phe	Thr	Asp	Tyr
			20					25					30		
Gly	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met
			35				40					45			
Gly	Trp	Ile	Asn	Thr	Tyr	Ile	Gly	Glu	Pro	Ile	Tyr	Ala	Asp	Ser	Val
	50					55					60				
Lys	Gly	Arg	Phe	Thr	Phe	Ser	Leu	Asp	Thr	Ser	Lys	Ser	Thr	Ala	Tyr
65					70					75				80	
Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
			85						90				95		
Ala	Arg	Gly	Tyr	Arg	Ser	Tyr	Ala	Met	Asp	Tyr	Trp	Gly	Gln	Gly	Thr
			100					105					110		
Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro
		115					120					125			
Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly
	130					135					140				
Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn
145					150					155					160

Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln
			165						170					175	
Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser
			180						185				190		
Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser
			195				200					205			
Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr
	210					215					220				
His	Thr	Cys	Ala	Ala											
225															

<210> 116
 <211> 1477
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic CDP870 nucleic acid sequence (sense strand)

<400> 116
 atgaaaaaga cagctatcgc aattgcagtg gccttggtg gtttcgctac cgtagcgcaa 60
 gctgacattc aaatgaccca gagcccatcc agcctgagcg catctgtagg agaccgggtc 120
 accatcactt gtaaagccag tcagaacgta ggtactaacg tagcctggta tcagcaaaaa 180
 ccaggtaaag ccccaaaagc cctcatctac agtgccctctt tcctctatag tgggtgtacca 240
 tacaggttca gcggtatccg tagtggtact gatttcaccc tcacgactag tagcctccag 300
 ccagaagatt togccactta ttactgtcaa cagtataaca tctaccact cacttcggt 360
 cagggtacta aagtagaaat caaacgtacg gtagcgcccc catctgtctt catcttccc 420
 ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgctgct gaataacttc 480
 tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 540
 caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 600
 acgctgagga aagcagacta cgagaaacac aaagcttacg cctgcgaagt caccatcag 660
 ggcctgagct caccagtaac aaaaagcttt aatagaggag agtggtgagg aggaaaaaaa 720
 aatgaagaaa actgctatag caattgcagt ggcgctagct ggtttcgcca ccgtggcgca 780
 agctgagggt cagctggtcg agtcaggagg cggctctgtg cagcctggcg gatcactgag 840
 attgtctgtg gctgcatctg gttacgtctt cacagactat ggaatgaatt gggttagaca 900
 ggccccggga aagggcctcg aatggatggg ttggattaat acttacattg gagagcctat 960
 ttatgctgac agcgtcaagg cgagattcac gttctctcta gacacatcca agtcaacagc 1020
 atacctcaa atgaatagcc tgagagcaga ggacaccgca gtgtactatt gtgctagagg 1080
 atacagatct tatgccatgg actactgggg ccagggtacc ctagtacag tctcctcagc 1140
 ttccaccaag ggcccatcgg tcttccccct ggcaccctcc tccaagagca cctctggggg 1200
 cacagcggcc ctgggctgcc tgggtcaagga ctacttcccc gaaccgggtga cgggtgctgtg 1260
 gaactcaggc gccctgacca gcggcggtgca caccttcccc gctgtcctac agtcctcagg 1320
 actctactcc ctacgacgagc tgggtgacct gccctccagc agcttgggca cccagacct 1380

 catctgcaac gtgaatcaca agcccagcaa caccaaggtc cacaagaaag ttgagcccaa 1440
 atcttgtgac aaaactcaca catgcgccgc gtgatga 1477

<210> 117
 <211> 1477
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic CDP870 nucleic acid sequence (anti-sense strand)

<400> 117

```
tcatacacgcg gcgcattgtgt gagttttgtc acaagatttg ggctcaactt tcttgtggac 60
cttggtgttg ctgggcttgt gattcacgtt gcagatgtag gtctgggtgc ccaagctgct 120
ggagggcacg gtcaccacgc tgcagagga gtagagtcct gaggactgta ggacagccgg 180
gaaggtgtgc acgccgctgg tcagggcgcc tgagttccac gacaccgtca ccggttcggg 240
gaagtagtcc ttgaccaggc agcccagggc cgctgtgccc ccagaggtgc tcttgaggga 300
gggtgccagg gggaagaccg atgggccctt ggtggaagct gaggagactg tgactagggt 360
accctggccc cagtagtcca tggcataaga tctgtatcct ctacacaaat agtacctgc 420
ggtgtcctct gctctcaggc tattcatttg gaggtatgct gttgacttgg atgtgtctag 480
agagaacgtg aatctcgctt tgacgctgtc agcataaata ggctctccaa tgtaagtatt 540
aatccaaccc atccattcga ggccctttcc cggggcctgt ctaacccaat tcattccata 600
gtctgtgaag acgtaaccag atgcagcaca ggacaatctc agtgatccgc caggctgcac 660
gagaccgctt cctgactcga ccagctgaac ctgagcttgc gccacggtgg cgaaaccagc 720
tagcgccact gcaattgcta tagcagtttt cttcattttt ttttctctct caacactctc 780
ctctattaaa gctttttgtt actggtgagc tcaggccctg atgggtgact tcgcaggcgt 840
aagctttgtg tttctcgtag tctgctttcc tcagcgtcag ggtgctgctg aggctgtagg 900
tgctgtcctt gctgtcctgc tctgtgacac tctcctggga gttaccgat tggaggcgt 960
tatccacctt ccactgtact ttggcctctc tgggataga gttattcagc aggcacacaa 1020
cagaggcagt tccagatttc aactgctcat cagatggcgg gaagatgaag acagatgggg 1080
ccgctaccgt acgtttgatt tctactttag taccctgacc gaatgtgagt gggtagatgt 1140
tatactgttg acagtaataa gtggcgaaat cttctggctg gaggctacta gtcgtgaggg 1200
tgaaatcagt accactaccg gatccgctga acctgtatgg tacaccacta tagaggaaaag 1260
aggcactgta gatgagggct tttggggctt tacctggttt ttgctgatac caggctacgt 1320
tagtacctac gttctgactg gctttacaag tgatggtgac ccggtctcct acagatgcgc 1380
tcaggctgga tgggctctgg gtcatttgaa tgtcagcttg cgctacggta gcgaaaccag 1440
ccaaggccac tgcaattgcg atagctgtct ttttcat 1477
```